Previous close | 1,479.45 |
Open | 1,475.25 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 1,472.60 - 1,497.60 |
52-week range | 942.30 - 1,519.00 |
Volume | |
Avg. volume | 1,978,635 |
Market cap | 1.206T |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 29.26 |
EPS (TTM) | 51.04 |
Earnings date | 24 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | 13.00 (0.88%) |
Ex-dividend date | 01 Aug 2024 |
1y target est | 1,448.09 |
Indian drugmakers, which have the U.S. market as a key segment, will sustain their revenue improvement in fiscal 2025 due to drug shortages in the United States, Mumbai-based India Ratings and Research said on Monday. India is a hub of bulk generic drug manufacturing and drugmakers including Dr Reddy's, Cipla, Sun Pharma derive a significant share of revenue from both the U.S. and Europe. The world's largest drug market is facing decade-high drug shortages, the research firm said in a note citing data from with Utah Drug Information Service.
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
Cipla's promoter group is looking to sell a 2.53% stake in India's third-largest drugmaker via a block deal worth 26.37 billion rupees (nearly $316 million), CNBC-TV18 reported on Tuesday, citing sources. The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said. Cipla did not immediately respond to a Reuters request for comment.